KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Other Non-Current Assets (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Other Non-Current Assets for 8 consecutive years, with $7.0 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Assets rose 9.43% to $7.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.0 million through Dec 2025, up 9.43% year-over-year, with the annual reading at $7.0 million for FY2025, 9.43% up from the prior year.
  • Other Non-Current Assets hit $7.0 million in Q4 2025 for Vir Biotechnology, roughly flat from $7.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $13.2 million in Q2 2025 to a low of $6.3 million in Q1 2025.
  • Historically, Other Non-Current Assets has averaged $7.3 million across 5 years, with a median of $7.0 million in 2025.
  • Biggest five-year swings in Other Non-Current Assets: surged 487.42% in 2021 and later decreased 25.45% in 2023.
  • Year by year, Other Non-Current Assets stood at $7.0 million in 2021, then decreased by 5.0% to $6.7 million in 2022, then fell by 3.12% to $6.4 million in 2023, then decreased by 1.32% to $6.4 million in 2024, then rose by 9.43% to $7.0 million in 2025.
  • Business Quant data shows Other Non-Current Assets for VIR at $7.0 million in Q4 2025, $7.0 million in Q3 2025, and $13.2 million in Q2 2025.